Keytruda Gains 12th Indication Approval in China for HER2-Negative Gastric Cancer
US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its immunotherapy...
MSD
FDA Approves Pfizer-Astellas-MSD Combo Therapy for Advanced Urothelial Cancer
Pfizer (NYSE: PFE), Astellas (TYO: 4503), and Merck, Sharp & Dohme (MSD; NYSE: MRK) have...
MSD’s Welireg Gains FDA Approval for Advanced Renal Cell Carcinoma
The US Food and Drug Administration (FDA) has granted an indication extension approval for Merck,...
MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...
MSD to Migrate IT Systems to AWS, Aiming for Faster Drug Discovery and Clinical Trials
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced plans to transition a significant portion...
Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...
MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics,...
Aurobindo Pharma’s China Plant Secures EU GMP Approval, Eyes Revenue Generation
India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Merck Reports 9% Global Sales Growth in Q3 2023, Boosted by Keytruda and Gardasil
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has reported a robust 9%...
MSD Halts Phase II Trials for Glutamate Modulator MK-1942 in Alzheimer’s and Depression
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of two Phase II...
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy
Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership...
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension
The US Food and Drug Administration (FDA) has granted priority review status to an indication...
EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...
Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial
Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...